Try our mobile app

Published: 2022-11-17 16:08:58 ET
<<<  go to RMD company page
8-K
RESMED INC US false 0000943819 0000943819 2022-11-16 2022-11-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 16, 2022

Date of Report (Date of earliest event reported)

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-15317   98-0152841

(State or Other Jurisdiction

of Incorporation)

   (Commission
File Number)		  

(I.R.S. Employer

Identification No.)

 

9001 Spectrum Center Boulevard
San Diego, California 92123
(Address of Principal Executive Offices) (Zip Code)

(858) 836-5000

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.004 par value   RMD   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”).

 

     For      Against      Abstain      Broker
Non-Votes		  
Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified:            

Carol Burt

      112,920,252        1,611,838        653,168        4,934,277  

Jan De Witte

      114,414,039        549,367        221,852        4,934,277  

Karen Drexler

      112,325,192        2,592,899        267,167        4,934,277  

Michael Farrell

      114,166,629        811,588        207,041        4,934,277  

Peter Farrell

      110,955,680        3,892,880        336,698        4,934,277  

Harjit Gill

      113,995,558        965,687        224,013        4,934,277  

John Hernandez

      113,649,577        1,311,352        224,329        4,934,277  

Richard Sulpizio

      102,238,286        12,686,008        260,964        4,934,277  

Desney Tan

      114,124,829        836,885        223,544        4,934,277  

Ronald Taylor

      102,459,467        12,464,667        261,124        4,934,277  
     For      Against      Abstain      Broker
Non-Votes		  
Item of business 2: Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023.      113,914,469        6,001,739        203,327     
     For      Against      Abstain      Broker
Non-Votes		  
Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our proxy statement (“say-on-pay”).      103,364,254        11,566,190        254,814        4,934,277  

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

    RESMED INC.
Date: November 17, 2022     By:  

/s/ David Pendarvis

      David Pendarvis
      Chief administrative officer, global general counsel and
secretary